Vaxart, Inc. Price Chart
Vaxart, Inc. NB11.DE Financial and Trading Overview
| Vaxart, Inc. stock price | 3.81 EUR |
| Previous Close | 3.45 EUR |
| Open | 3.81 EUR |
| Bid | 0 EUR x N/A |
| Ask | 0 EUR x N/A |
| Day's Range | 3.81 - 3.81 EUR |
| 52 Week Range | 3.4 - 8.26 EUR |
| Volume | 250 EUR |
| Avg. Volume | 66 EUR |
| Market Cap | 481.61M EUR |
| Beta (5Y Monthly) | 0.784507 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.61 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
NB11.DE Valuation Measures
| Enterprise Value | 467.93M EUR |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 690.97107 |
| Price/Book (mrq) | 5.7552867 |
| Enterprise Value/Revenue | 671.35 |
| Enterprise Value/EBITDA | -4.482 |
Trading Information
Vaxart, Inc. Stock Price History
| Beta (5Y Monthly) | 0.784507 |
| 52-Week Change | -28.22% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 8.26 EUR |
| 52 Week Low | 3.4 EUR |
| 50-Day Moving Average | 4.12 EUR |
| 200-Day Moving Average | 5.09 EUR |
NB11.DE Share Statistics
| Avg. Volume (3 month) | 66 EUR |
| Avg. Daily Volume (10-Days) | 25 EUR |
| Shares Outstanding | 126.41M |
| Float | 134.82M |
| Short Ratio | N/A |
| % Held by Insiders | 1.69% |
| % Held by Institutions | 33.20% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor | 1:6 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -15943.90% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -42.064% |
| Return on Equity (ttm) | -84.17% |
Income Statement
| Revenue (ttm) | 697K EUR |
| Revenue Per Share (ttm) | 0.005 EUR |
| Quarterly Revenue Growth (yoy) | 694.10% |
| Gross Profit (ttm) | -80947000 EUR |
| EBITDA | -104393000 EUR |
| Net Income Avi to Common (ttm) | -107797000 EUR |
| Diluted EPS (ttm) | -0.61 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 70.21M EUR |
| Total Cash Per Share (mrq) | 0.52 EUR |
| Total Debt (mrq) | 21.52M EUR |
| Total Debt/Equity (mrq) | 23.97 EUR |
| Current Ratio (mrq) | 4.835 |
| Book Value Per Share (mrq) | 0.662 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -94126000 EUR |
| Levered Free Cash Flow (ttm) | -55538000 EUR |
Profile of Vaxart, Inc.
| Country | Germany |
| State | CA |
| City | South San Francisco |
| Address | 170 Harbor Way |
| ZIP | 94080 |
| Phone | 650 550 3500 |
| Website | https://vaxart.com |
| Industry | |
| Sector(s) | |
| Full Time Employees | 164 |
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase II clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine, an oral vaccine platform, which is in preclinical stage; coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection; human papillomavirus therapeutic vaccine that targets HPV 16 and HPV 18 for cervical cancers and precancerous cervical dysplasia. The company has license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
Q&A For Vaxart, Inc. Stock
What is a current NB11.DE stock price?
Vaxart, Inc. NB11.DE stock price today per share is 3.81 EUR.
How to purchase Vaxart, Inc. stock?
You can buy NB11.DE shares on the XETRA exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Vaxart, Inc.?
The stock symbol or ticker of Vaxart, Inc. is NB11.DE.
How many shares does Vaxart, Inc. have in circulation?
The max supply of Vaxart, Inc. shares is 126.41M.
What is Vaxart, Inc. Price to Earnings Ratio (PE Ratio)?
Vaxart, Inc. PE Ratio is now.
What was Vaxart, Inc. earnings per share over the trailing 12 months (TTM)?
Vaxart, Inc. EPS is -0.61 EUR over the trailing 12 months.